PDCD1 and non-small cell lung carcinoma: In advanced NSCLC (non-small cell lung cancer) patients treated with nivolumab (monoclonal IgG4 antibody that binds to PD-1 receptors), an increased or stable sPD-1 level was correlated with longer PFS (progression free survival) and OS (overall survival) while a high percent of NSCLC patients with increased levels of sPD-L1, treated with another anti-PD1, pembrolizumab combined with low doses of chemotherapy, exhibited progressive disease [32].